• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic-backed study implants 1st Alzheimer’s patient with brain “pacemaker”

Medtronic-backed study implants 1st Alzheimer’s patient with brain “pacemaker”

August 7, 2012 By MassDevice staff

Deep brain stimulation image

Researchers in the U.S. and Canada launched a clinical trial evaluating the safety and efficacy of deep-brain stimulation in treatment of mild Alzheimer’s disease.

The study will enroll 20 people aged 55-80 with Medtronic’s (NYSE:MDT) deep brain stimulation technology, surgically implanted devices that are similar to a cardiac pacemaker and that deliver electrical pulses to targeted areas of the brain.

The trial, conducted by Functional Neuromodulation Ltd., will use Medtronic’s DBS therapy to target a specific area considered a "major inflow and output pathway in the brain’s memory circuit," according to a press release.

Each patient in the study, dubbed the ADvance trial, will receive the implant. Researchers will compare the effects of the implant turned on and turned off in a randomized, double-blind manner for a follow-up period of 12 months, according to the report. After the follow-up period patients with the device turned off may elect to flip the switch and activate their implants.

"As people are increasingly aware, there is an urgent need for new and better ways to treat Alzheimer’s," Functional Neuromodulation co-founder and CEO Dan O’Connell said in prepared remarks. "DBS is a promising new approach that has a successful track record in a number of other brain disorders."

Medtronic helped pioneer DBS therapy, which initially won European regulatory approval in 1995 and FDA approval in 1997. Earlier this year Medtronic enrolled the 1st patient into its Medtronic Registry for Epilepsy, a database tracking the safety, efficacy and quality of life of patients receiving deep-brain stimulation for treatment of drug-resistant epilepsy.

Medtronic’s DBS won CE Mark approval for epileptic patients in the European Union in August 2010, but has yet to gain similar approval in the U.S., where it is under humanitarian device exemption for a number of conditions, including treatment-resistant obsessive-compulsive disorder and advanced Parkinson’s disease. 

St. Jude Medical‘s (NYSE:STJ) Libra and LibraXP systems are also cleared for treating symptoms of Parkinson’s. The medical device giant is also investigating DBS in treatment of severe depression through its BROADEN trial, building on previous St. Jude work that showed that 62% of patients experienced at least 40% reduction in symptoms of depression at 6 months of treatment. Of those patients, more than 90% maintained the improvement after a year.

Filed Under: Neuromodulation/Neurostimulation, News Well Tagged With: Alzheimer's disease, Clinical Trials, stjudemedical

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy